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Background: The chemokine interleukin-8 (IL-8) and its receptor CXCR2 contribute to chemotactic responses in
Alzheimer’s disease (AD); however, properties of the ligand and receptor have not been characterized in animal
models of disease. The primary aim of our study was to examine effects of pharmacological antagonism of CXCR2
as a strategy to inhibit receptor-mediated inflammatory reactivity and enhance neuronal viability in animals
receiving intrahippocampal injection of amyloid-beta (Aβ1–42).
Methods: In vivo studies used an animal model of Alzheimer’s disease incorporating injection of full-length Aβ1–42 into
rat hippocampus. Immunohistochemical staining of rat brain was used to measure microgliosis, astrogliosis, neuronal
viability, and oxidative stress. Western blot and Reverse Transcription PCR (RT-PCR) were used to determine levels
of CXCR2 in animal tissue with the latter also used to determine expression of pro-inflammatory mediators.
Immunostaining of human AD and non-demented (ND) tissue was also undertaken.
Results: We initially determined that in the human brain, AD relative to ND tissue exhibited marked increases in
expression of CXCR2 with cell-specific receptor expression prominent in microglia. In Aβ1–42-injected rat brain,
CXCR2 and IL-8 showed time-dependent increases in expression, concomitant with enhanced gliosis, relative to
controls phosphate-buffered saline (PBS) or reverse peptide Aβ42–1 injection. Administration of the competitive
CXCR2 antagonist SB332235 to peptide-injected rats significantly reduced expression of CXCR2 and microgliosis,
with astrogliosis unchanged. Double staining studies demonstrated localization of CXCR2 and microglial immunoreactivity
nearby deposits of Aβ1–42 with SB332235 effective in inhibiting receptor expression and microgliosis. The numbers of
neurons in granule cell layer (GCL) were reduced in rats receiving Aβ1–42, compared with PBS, with administration of
SB332235 to peptide-injected animals conferring neuroprotection. Oxidative stress was indicated in the animal model
since both 4-hydroxynonenal (4-HNE) and hydroethidine (HEt) were markedly elevated in Aβ1–42 vs PBS-injected rat brain
and diminished with SB332235 treatment.
Conclusion: Overall, the findings suggest critical roles for CXCR2-dependent inflammatory responses in an AD animal
model with pharmacological modulation of the receptor effective in inhibiting inflammatory reactivity and conferring
neuroprotection against oxidative damage.
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Chronic inflammation is an inherent ongoing process
in the progression of Alzheimer’s disease [1–3]. How-
ever, the specific mechanisms by which sustained in-
flammatory reactivity contributes to the progressive
neuronal degeneration underlying loss of cognition in
Alzheimer’s disease (AD) brain are not well under-
stood. Some evidence suggests limited benefits of non-
steroidal anti-inflammatory drugs (NSAIDS) [4] with
the relatively small extent of drug efficacy attributed
to previous deterioration in cognitive function in AD
individuals prior to medication. Another possibility is
that inflammatory reactivity in AD brain is manifest
from activation of multiple pathways other than
cyclooxygenase-dependent activity targeted by NSAIDS.
A critical component of inflammatory response is a
chemokine-mediated mobilization of microglia in re-
sponse to peptide deposition [3, 5–7]. A spectrum of
chemokines contributes to inflammatory responses in
disease [8, 9], with some evidence suggesting a promin-
ent role for interleukin-8 (IL-8) in AD pathology. Gene
microarray analysis has shown that IL-8 exhibits the lar-
gest increase in expression of any inflammatory factor in
human microglia incubated with amyloid-beta (Aβ1–42)
[10]. This same group also reported dose-dependent in-
creases in production of IL-8 in human microglia stimu-
lated with peptide [11]. Elevated cerebrospinal fluid (csf)
levels of IL-8 have been documented in AD brain rela-
tive to controls [12]. Interestingly, IL-8 has been re-
ported to potentiate Aβ1–42-induced expression and
production of a number of pro-inflammatory cytokines
in cultured human microglia [13].
Immunostaining for the IL-8 receptor CXCR2 has
demonstrated receptor association with neuritic pla-
ques in AD tissue [5, 14]. However, CXCR2 also
ransduces IL-8-dependent cellular inflammatory che-
mokine responses in the periphery and brain. In the
former case, the receptor is expressed by infiltrating
neutrophils in chronic obstructive pulmonary disease
(COPD) with inhibition of CXCR2-mediated inflam-
matory responses effective in attenuating lung damage
[15]. Prominent CXCR2 activity in activated microglia
has been reported in damaged brain with antagonism
of receptor effective in reducing inflammation and
promoting recovery in lesioned spinal cord [16], fol-
lowing traumatic brain insult [17] and in animal tumor
models [18].
At present, pharmacological modulation of CXCR2
has not been examined in animal models of AD. We
posited that given the high levels of IL-8 in AD brain
that pharmacological inhibition of CXCR2 could serve
as a novel strategy to protect neurons exposed to inflam-
matory microenvironments. To examine this hypothesis,
we have used the compound SB332235, a selectiveinhibitor of CXCR2 in macrophage cells [15, 19], as a re-
ceptor antagonist to attenuate microglial inflammatory
reactivity induced by Aβ1–42 intrahippocampal injection.
Specifically, SB332235 has been examined in vivo as a
modulator of CXCR2 cell-specific association, gliosis,
microglial chemotactic response, oxidative stress factors,
and neuronal viability.Methods
Human brain tissue
Preparation of human ND and AD sections
The procedures used to isolate postmortem tissue have
been described [20]. Entorhinal cortical sections from
six ND cases (ages from 60 to 85 years, postmortem in-
tervals, 6–24 h) and six AD cases (ages from 64 to
87 years, postmortem intervals, 5–10 h) were obtained
from the Kinsmen Laboratory brain bank at the University
of British Columbia (UBC, Vancouver, British Columbia,
Canada). Average age of individuals and mean postmor-
tem delay did not differ significantly between AD and ND
cases. The ND cases exhibited no clinical or pathological
history of dementia or other neurological disorders. Five
of the ND cases were scored as Braak stage I with one
case scored as Braak stage II [21]. All cases of AD met the
clinical criteria and postmortem confirmation for AD [22]
and were characterized by high levels of plaque density
and neurofibrillary tangles. The AD cases were rated as
Braak V (one case) or VI (five cases).Immunohistochemical staining and analysis in human ND
and AD sections
For immunofluorescent staining, free-floating sections
(30 μm) from ND and AD tissues were washed in
phosphate-buffered saline (PBS) with Triton X-100
(PBST; 0.01 M PBS, pH 7.4, containing 0.3 % Triton X-
100) and transferred into 5 % skim milk in PBST for 1 h.
Sections were then incubated for 48 h at 4 °C with anti-
bodies for CXCR2, HLA-DR, or GFAP and then rinsed
in PBST and incubated with Alexa Fluor 488-conjugated
goat anti-rabbit IgG (1:200; Invitrogen) for 1 h at room
temperature. After washing in PBST, sections were
mounted on glass slides and coverslipped with Prolong
Gold anti-fading agent (Invitrogen). For double-
immunofluorescence staining [23], free-floating sec-
tions were incubated for 48 h at 4 °C with a mixture of
two primary antibodies: CXCR2/HLA-DR and CXCR2/
GFAP. After incubation with the indicated primary
antibodies, sections were rinsed in PBST and incubated
for 1 h at room temperature with a mixture of Alexa
Fluor 488 goat anti-rabbit IgG (1:200; Invitrogen) and
Alexa Fluor 594 goat anti-mouse IgG secondary anti-
body (1:200; Invitrogen).
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Surgical procedures. All animal procedures were ap-
proved by the UBC Animal Care Ethics Committee, with
adherence to guidelines of the Canadian Council on
Animal Care. Male Sprague Dawley rats (Charles River
Laboratories, Montreal, QC, Canada) weighing 280–
300 g were used for in vivo studies. In brief, rats were
injected intraperitoneal (ip) with an anesthetic mixture
of ketamine hydrochloride (100 mg/kg; Bimeda-MTC,
Cambridge, ON, Canada) and xylazine hydrochloride
(10 mg/kg; Bayer Inc., Etobicoke, ON, Canada) and were
placed in a stereotaxic apparatus (David Kopf Instru-
ments, Tujunga, CA, USA). Animals received stereotaxic
injection of Aβ1–42 or controls (PBS or reverse peptide
Aβ42–1) as previously described [6, 24–26]. Following
skin incision to expose the skull, peptides (California
Peptides, Napa, CA, USA) were slowly injected (0.2 μl/
min) into the dentate gyrus region of rat hippocampus.
Injection coordinates were as follows: anterior-posterior
(AP), −3.3 mm; medial-lateral (ML), −1.6 mm; dorsoven-
tral (DV), −3.2 mm; all measurements from bregma.
Preparation and administration of chemicals
Amyloid peptide. The procedures for preparation of
amyloid-beta peptide for intrahippocampal injection
have been described [6, 25, 26]. Full-length Aβ1–42 or re-
verse peptide Aβ42–1 (California Peptide, Napa, CA,
USA) was first dissolved in 35 % acetonitrile (Sigma) and
further diluted to 500 μM with incremental additions of
PBS with vortexing. The peptide solution was subse-
quently incubated at 37 °C for 18 h to promote fibrilliza-
tion and aggregation and stored at 20 °C [11, 24].
Peptides (2 nmol) were injected for durations of 1, 3,
and 7 days in this work.
SB332235. This compound was kindly donated by
GlaxoSmithKline (709 Swedeland Road, King of Prussia,
PA, USA). The compound was dissolved in a saline solu-
tion and applied by ip injection at a single dose of 1 mg/
kg at the time of peptide injection. SB332235 has been
characterized as a specific antagonist for CXCR2-
mediated functional responses [15, 27].
Immunohistochemical staining of rat brain
Animals were transcardially perfused with heparinized
cold saline followed by 4 % paraformaldehyde under
ketamine/xylazine anesthesia. Brains were then removed,
postfixed, cryoprotected, and cut into 40-μm sections
[6]. Free-floating sections were processed for immuno-
histochemistry as described previously [6, 24, 26].
Briefly, sections were incubated in PBS containing 1 %
bovine serum albumin, normal goat serum (NGS), and
0.2 % Triton X-100 (Sigma-Aldrich, St Louis, MO, USA)
for 1 h. Sections were incubated overnight at 4 °C withthe following primary antibodies: anti-glial fibrillary
acidic protein, a marker for astrocytes (GFAP; 1:1000;
Sigma-Aldrich), anti-neuronal nuclei (NeuN; 1:500;
Chemicon, Temecula, CA, USA), and two specific micro-
glial antibodies (anti-ionized calcium-binding adapter
molecule 1 (Iba-1; 1:500; Wako Chemicals, Richmond VA,
USA) and HLA-DR (1:1000; Dako, Mississauga, ON,
Canada). Other antibodies used included ones for CXCR2
(1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
Aβ1–42 (1:100; Dako), and 4-hydroxynonenal (4-HNE,
1:500 Jaica, Shizuoka, Japan). Sections were rinsed in PBS
with 0.5 % BSA and incubated with secondary antibodies
conjugated with Alexa Fluor 488 or 594 (1:200; Invitrogen,
Burlington, ON, Canada) for 1 h in the dark.
In this work, double immunostaining was also carried
out for microglial and astrocytic CXCR2 expression. In
the former case, since Iba-1 antibody was raised in
rabbit, mouse OX-42 (1:500; Serotec, Oxford, UK) was
used for staining of receptor in microglia. CXCR2 asso-
ciation with astrocytes used respective antibodies for re-
ceptor/cell of CXCR2/GFAP. Sections were rinsed in
PBS with 0.5 % BSA and incubated with a mixture of
secondary antibodies (Alexa Fluor 488 and 594; 1:100;
Invitrogen).
To determine production of reactive oxygen species
(ROS), peptide-injected animals received ip injection of
1 mg/kg hydroethidine (HEt; Molecular Probes) which is
oxidized to ethidium bromide in the presence of super-
oxide radicals [28]. At 3 h following HEt injection, animals
were killed by transcardiac saline perfusion and brains
were removed and frozen. Coronal sections (40-μm thick-
ness) of hippocampus were examined under a Zeiss Axio-
plan 2 fluorescent microscope equipped with an ethidium
filter and digital video camera (DVC) system (Diagnostic
Instruments, Sterling Heights, MI, USA).Immunohistochemical analysis of rat brain
Quantification of immunohistochemical staining followed
published procedures [25, 26, 29]. Digitized images were
obtained with a Zeiss Axioplan 2 fluorescent microscope
equipped with a DVC system. Quantitative image analysis
for the immunostained rat hippocampal sections was per-
formed on three equally spaced sections through the level
of the injection site. In each stained section, hippocampal
boundaries were outlined with the granule cell layer
(GCL) denoted as the superior blade of dentate gyrus.
The molecular layer (ML) was then defined as the re-
gion between GCL border and hippocampal fissure.
Neuronal viability and lipid peroxidation were mea-
sured in GCL, and glial responses and superoxide pro-
duction were measured in adjacent ML. Digitized
images were analyzed using Northern Eclipse software
(Empix Imaging, Mississauga, ON, Canada).
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The specific protocols for Reverse Transcription PCR (RT-
PCR) closely followed those outlined in previous work from
this laboratory [26, 29, 30]. Anesthetized animals were
killed by decapitation at 1, 3, and 7 days after peptide injec-
tion. The control animals were killed at 3 days after PBS or
reverse peptide Aβ42–1 injection. Brains were removed, and
hippocampal tissues were freshly dissected onto cold metal
tissue matrices (Harvard Apparatus) and quickly frozen in
liquid nitrogen. Total RNA was extracted using Trizol re-
agent (Invitrogen) and processed using reverse transcript-
ase; cDNA products were amplified by PCR using a
GeneAmp thermal cycler (Applied Biosystems, Foster City,
CA, USA) with Taq polymerase. PCR primers (β-actin was
used as a reaction control) were as follows: CXCR2: for-
ward, 5′-GTC AGG ATC CAA GTT TAC CTC AAA
AAT GG-3′; reverse, 5′-CTT AGG TCG ACG GTC TTA
GAG AGT AGT GG-3′. The primers for IL-8 were as fol-
lows: forward, 5′-ACT GAG AGT GAT TGA GAG TGG
AC AC-3′; reverse 5′-AAC CCT CTG CAC CCA GTT
TTC-3′. Relative mRNA levels (stimulated values normal-
ized to controls) were obtained using NIH ImageJ software
1.24 (National Institute of Health, Bethesda, MD, USA).
Western blot for CXCR2
Total protein from rat hippocampal tissue was used for
Western blot analysis. Protein samples (50 μg) were sub-
jected to SDS-PAGE prior to transfer onto a PVDF mem-
brane (Millipore, Bedford, MA, USA), blocked with either
5 % skim milk or bovine serum albumin, and probed with
anti-CXCR2 (1:200; Santa Cruz Biotechnology) and β-actin
(1:5000; Abcam, Cambridge, MA, USA). HRP-conjugated
secondary antibodies (GE Healthcare biosciences, Piscat-
away, NJ, USA) were used to develop immunoblots which
were processed using enhanced chemiluminescence (ECL)
detection (GE Healthcare Biosciences). Band intensities
were quantified using ImageJ software (NIH).
Statistical analysis
Results are presented as mean ± SEM. The statistical
analysis was performed using a one-way ANOVA,
followed by the Student–Newman–Keuls multiple com-
parison test or Student’s t test (GraphPad Prism 3.0;
Graph Pad) with significance level set at p < 0.05.
Results
CXCR2 expression in AD and ND brain sections
Brain tissue from AD and ND individuals was first ana-
lyzed for expression of CXCR2. Representative immuno-
staining demonstrated low levels of CXCR2 in areas of
entorhinal cortex from ND tissue with a considerably el-
evated expression of the IL-8 receptor in AD sections
(Fig. 1a). Quantification for CXCR2 expression is pre-
sented in Fig. 1b (N = 6 for each of AD/ND). The areadensity of CXCR2 was increased 4.4-fold in AD, com-
pared with ND, brain tissue.
Since the focus of the study was pharmacological
modulation of CXCR2-mediated inflammatory reactivity
in vivo, we also examined receptor expression and the
microglial marker HLA-DR in AD brain. Representative
single and double staining for CXCR2/HLA-DR in cor-
tical brain sections are presented in Fig. 1c. The results
demonstrated considerable co-localization for the two
markers, a similar finding was made in all AD cases.
Typical expression of CXCR2/HLA-DR in AD hippo-
campal brain tissue is shown in Fig. 1d. Both markers
showed a marked extent of co-localization throughout
areas of hippocampus. Although hippocampal tissue was
limited in availability, similar co-localization between re-
ceptor and HLA-DR was evident in sections from N = 3
other AD cases. Although we did not attempt quantifica-
tion for overall merged staining for CXCR2/HLA-DR,
the findings from AD cortical and hippocampal tissue
implicated microglial CXCR2 as a putative inflammatory
mediator in the progression of AD pathology. Experi-
ments were then designed to examine effects of pharma-
cological antagonism of CXCR2 in animal brain.Time-dependent CXCR2 expression in vivo
An Aβ1–42 intrahippocampal-injection animal model [6,
26, 30, 31] was used to characterize glial reactivity and
neuronal viability and their pharmacological modula-
tions with the CXCR2 antagonist, SB332235. Initial ex-
periments examined the expression of CXCR2 and a
ligand for the receptor, IL-8 at different durations fol-
lowing peptide injection.
Representative RT-PCR for CXCR2, and also for IL-8,
is shown for durations of Aβ1–42 injections of 1, 3, and
7 days (Fig. 2a). Controls used both PBS and reverse
peptide (Aβ42–1) with results shown at a single time
point of 3 days post-injection. The results showed levels
of both CXCR2 and IL-8 were higher at all time points
post-Aβ1–42 injection compared with 3 days controls
(PBS and Aβ42–1). Interestingly, both CXCR2 and ligand
IL-8 were maximally expressed at 3 days following pep-
tide injection.
Semi-quantification of data for CXCR2 expression (N =
5 animals/group) for the different peptide injection times
is shown (Fig. 2b). Expression of CXCR2 (left bar graph)
was increased with Aβ1–42 by respective amounts of 1.4-
fold, 3.1-fold, and 1.9-fold (1, 3 and 7 days Aβ1–42) com-
pared with 3 days PBS injection; the 3 and 7 days values
representing significant increases. The corresponding data
for IL-8 are presented in Fig. 2b (right bar graph) with ex-
pression of the chemokine (N = 5 animals/group) in-
creased by 3.3-fold, 6-fold, and 4-fold with peptide
injections (respective values for 1, 3, and 7 days
Fig. 1 Staining patterns of CXCR2 in AD and ND cortical and hippocampal brain sections. a Representative CXCR2 immunoreactivity (ir) in cortical
regions of ND and AD brain; scale bar represents 40 μm. b Quantification of CXCR2 area density in ND and AD sections (N = 6 cases for each);
asterisk denotes p < 0.05. c Double staining of CXCR2 (green), HLA-DR-(+)ve microglia (red) and merged CXCR2/HLA-DR in cortical AD brain.
d Double staining for the same markers in hippocampal brain sections; scale bar for c (and d, is same as c) is 100 μm
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represent significant increases.
Additional experiments focused on CXCR2 expression
in peptide-injected hippocampus. We used immunohis-
tochemical staining in the ML of dentate gyrus to
measure CXCR2 levels at the single time point of 3 days
post-Aβ1–42 injection. As shown in Fig. 2c, relatively low
levels of CXCR2 immunoreactivity (ir) were evident with
either PBS (left panel) or reverse peptide (middle panel)
controls. However, Aβ1–42-injected animals exhibited a
marked increase in CXCR2 expression (right panel) with
association of receptor in cells showing a glial morph-
ology. Quantification of immunostaining data is pre-
sented in Fig. 2d (N = 5 animals/group). The area density
of CXCR2 was considerably increased (by 6.3-fold) with
Aβ1–42, compared with PBS, injection. Thus, upregula-
tion of CXCR2 expression is a characteristic response to
peptide injection in the AD animal model.
Western blot analysis was done to demonstrate pro-
tein expression of CXCR2. As shown in Fig. 2e, CXCR2
was minimally expressed in control, progressively in-
creased at 1 and 3 days post-intrahippocampal injection
of Aβ1–42 and returned to near control level at 7 days
following peptide injection. Quantification of CXCR2
levels (N = 4 animals per group) showed that at 1 daypost-Aβ1–42 injection, receptor expression was elevated
but not significantly different from control. CXCR2 was
maximally expressed at 3 days post-peptide and signifi-
cantly increased (by 40 %) from levels with PBS
injection.
Cell-specific expression of CXCR2 in vivo
The patterns of CXCR2 immunostaining shown in Fig. 1
for human AD tissue indicated prominent receptor ex-
pression in microglia. Double immunostaining was used
to study glial-dependent expression of CXCR2 in control
and peptide-injected rat hippocampus. At maximal
CXCR2 expression (3 days of Aβ1–42 injection), double
staining was carried out to determine association of IL-8
receptor with microglia (OX-42 marker) and astrocytes
(GFAP marker). As for previous studies on gliosis in the
AD animal model, gliosis was measured in the ML re-
gion of the dentate gyrus. This procedure would serve to
minimize contributions from receptor expression in
neurons.
Representative patterns of immunostaining are shown
for OX-42-(+)ve microglia and CXCR2 in Fig. 3a (3 days
post-Aβ1–42 injection). Considerable association of the
two markers was evident in the merged staining (right
panel) with results indicating marked Aβ1–42 stimulation
Fig. 2 Expression of CXCR2 and IL-8 in ML region of rat dentate gyrus. a Representative RT-PCR for CXCR2 and IL-8 in controls (3 days post-
injection of PBS or reverse peptide Aβ42–1) and in Aβ1–42-injected rat brain (1, 3, and 7 days post-injection); β-actin was used as a reaction
standard. b Semi-quantification of RT-PCR for CXCR2 (left bar graph) and IL-8 (right bar graph); N = 5 animals per treatment group. c Typical CXCR2
ir for PBS, Aβ42–1, and Aβ1–42 (3 days post-injection); scale bar is for 70 μm. d Overall CXCR2 area density for the different animal groups (N = 4
animals per treatment group). Asterisk denotes p < 0.05 for Aβ1–42 vs PBS. e Representative Western blot for CXCR2 in control (3 days) and 1,3,
and 7 days post-peptide injection. The bar graph shows relative CXCR2 levels for control and different durations of peptide injection (N = 4
animals per group)
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CXCR2 is presented in Fig. 3b. Merged staining indi-
cated that a relatively low proportion of astrocytes were
co-localized with CXCR2 (right panel, Fig. 3b).
The immunostaining results with both OX-42 and
GFAP suggested considerable gliosis was induced in
peptide-injected rat hippocampus which was examined
as a target for pharmacological modulation of CXCR2
using the receptor antagonist, SB332235.
Effects of CXCR2 antagonist SB332235 on gliosis
Initial experiments were designed to examine effects of
CXCR2 antagonism, at a single time point of 3 days
post-peptide injection, on microgliosis and astrogliosis.
Sections were isolated from the ML region of hippo-
campus to minimize neuronal expression of receptor.
Animal groups received PBS and reverse peptidecontrols, Aβ1–42, Aβ1–42 with SB332235 treatment and
SB332235 alone.
Representative microglial ir (Iba-1 marker) is shown in
Fig. 4a and indicates relatively low numbers of cells in
PBS control (upper left panel) and with SB332235 ap-
plied alone (upper right panel). Considerable microglio-
sis was induced following peptide injection (lower left
panel). Treatment of peptide-injected animals with
SB332235 was effective in attenuating microglial re-
sponses (lower right panel).
Quantification of data is presented in Fig. 4b (N = 5
animals/group) and also includes reverse peptide Aβ42–1
as a control animal group. Both PBS and reverse peptide
demonstrated similar low values of microglial Iba-1 ir.
Iba-1 ir, used as an index of microgliosis, was increased
3.5-fold in Aβ1–42, compared with PBS, injected rat
brain. Peptide-administered animals receiving SB332235
Fig. 3 Cell-specific expression of CXCR2 in ML of dentate gyrus. a
Representative single and merged staining of OX-42-(+)ve microglia
with CXCR2 at 3 days post-Aβ1–42 intrahippocampal injection; scale bar
is for 20 μm. b Single and merged staining of GFAP-(+)ve astrocytes
with CXCR2 after 3 days of peptide injection; scale bar is for 15 μm
Fig. 4 Effects of SB332235 on gliosis in ML region of dentate gyrus in pept
following 3 days injections with PBS (upper left panel), SB332235 alone (upp
right panel). b Overall area density for Iba-1 (N = 5 per treatment group). c
SB332235 alone (upper right panel), Aβ1–42 (lower left panel), and Aβ1–42 + S
treatment group). Scale bars are for 80 μm. *p < 0.05 Aβ1–42 vs PBS; #p < 0.0
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compared with rats receiving Aβ1–42 in the absence of
the CXCR2 antagonist. Similar levels of Iba-1 ir were
measured with SB332235 administered alone and with
PBS and Aβ42–1 controls.
Typical astrocytic staining (GFAP marker) indicated a
considerably enhanced response in Aβ1–42-injected rats
relative to PBS controls (Fig. 4c, left panels). Interest-
ingly, unlike the results for microglia, astrogliosis
remained elevated with SB332235 treatment of peptide-
injected animals (lower right panel). GFAP staining
with SB332235 applied separately (upper right panel)
was similar to PBS control. Overall (N = 5 animals/
group), peptide-injected hippocampus demonstrated an
increased astrogliosis (by 3.5-fold) compared with PBS
(Fig. 4d). In the presence of SB332235 application with
Aβ1–42, GFAP ir was reduced by 14 %, an insignificant
change compared with no drug treatment. Levels of
GFAP were not significantly different between animals
receiving SB332235 treatment and PBS or reverse pep-
tide controls.ide-injected hippocampus. a Representative microgliosis (Iba-1 marker)
er right panel), Aβ1–42 (lower left panel), and Aβ1–42 + SB332235 (lower
Representative astrogliosis (GFAP marker) for PBS (upper left panel),
B332235 (lower right panel). d Overall area density for GFAP (N = 5 per
5 Aβ1–42 + SB332235 vs Aβ1–42
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microglial chemotaxis nearby Aβ1–42 deposits
Previous work has indicated microglial chemotactic re-
sponses in the Aβ1–42 injection animal model as an ini-
tial inflammatory response to deposition of peptide [6,
7]. The consequence of this rapid response is the spatial
localization of microgliosis and possibly upregulated
CXCR2 ir in the vicinity of peptide deposits in the ML
layer of dentate gyrus. Experiments were designed to
examine chemotaxis in vivo and to measure SB332235
modulation of receptor expression and gliosis nearby
amyloid deposits.
We determined immunoreactivities of CXCR2, Iba-1,
and GFAP within 300 μm of Aβ deposits in the ML re-
gion. The procedure defined quadrants of ML regions
with a focal point denoted by Aβ plaque deposition.
Representative staining for CXCR2 in proximity toFig. 5 Effects of SB332235 on area density for CXCR2 and microglia and as
Representative CXCR2 ir nearby Aβ1–42 (3 days post-Aβ1–42 injection) in the
scale bar is for 50 μm. b Overall CXCR2 area density (N = 5 per group) in a
nearby Aβ1–42 in the absence (left panel) and presence (right panel) of SB33
(N = 5 per group) in regions within 300 μm of peptide. e Representative GF
of SB332235 (right panel); scale bar is for 30 μm. f Overall GFAP area densit
vs Aβ1–42 + SB332235peptide is shown in the absence (left column) and pres-
ence (right column) of SB332235 treatment of peptide-
injected (3 days) animals (Fig. 5a). The distribution of
CXCR2 ir was concentrated nearby Aβ deposits in
peptide-injected hippocampus (left panel, Fig. 5a) with
SB332235 effective in reducing receptor expression
when administered with peptide (right panel, Fig. 5a).
Overall (N = 5 animals/group), CXCR2 expression in
proximity to Aβ was diminished by 45 % with applica-
tion of SB332235 to peptide-injected animals (Fig. 5b).
Representative patterns of microglial expression (Iba-1
marker) are presented in Fig. 5c. Numbers of microglia
were concentrated nearby Aβ then diminished with dis-
tance from deposits in both the absence (left panel) and
presence (right panel) of SB332235 treatment of rats.
Overall (N = 5 animals/group), SB332235 significantly
inhibited Iba-1 ir by 57 % (Fig. 5d). The predominancetrocyte responses in proximity to peptide deposits in ML region. a
absence (left panel) and presence (right panel) of SB332235 treatment;
single quadrant within 300 μm of peptide. c Representative Iba-1 ir
2235 treatment; scale bar is for 30 μm. d Overall Iba-1 area density
AP ir nearby peptide deposits in the absence (left panel) and presence
y (N = 5 per group) within 300 μm of peptide. *p < 0.05 for Aβ1–42
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microglial chemotactic responses to Aβ1–42 deposits.
Typical GFAP ir in Aβ1–42-injected animals, with and
without SB332235 treatment, is presented in Fig. 5e.
Similar homogenous distributions of astrocytic ir were
evident in the presence, and absence, of CXCR2 receptor
antagonist (left and right panels, Fig. 5e). Quantification
of GFAP area density (N = 5 animals/group) is presented
in Fig. 5f. The overall GFAP ir was not significantly dif-
ferent between untreated peptide-injected rats or ani-
mals receiving SB332235 application. In summary,
microgliosis and CXCR2 area density are enhanced
nearby Aβ with SB332235 effective in attenuating both
responses.
Effects of SB332235 on viability of GCL neurons and lipid
peroxidation
Neuronal viability
The neuroprotective efficacy of SB332235 administration
to peptide-injected animals (3 days post-injection) was
determined using NeuN as a marker for GCL neurons inFig. 6 Neuroprotective and lipid peroxidation effects of SB332235 on GCL
(upper left panel), SB332235 alone (upper right panel), Aβ1–42 (lower left pane
post-injection; scale bar represents 50 μm. b Area density of NeuN for the a
peroxidation (4-HNE marker) levels following 3 days intrahippocampal injec
42 (lower left panel), and Aβ1–42 + SB332235 (lower right panel). Scale bar is f
N = 5 per group. *p < 0.05 for Aβ1–42 vs PBS and #p < 0.05 for Aβ1–42 vs Aβ1dentate gyrus. Typical staining patterns for neurons for
the different animal groups are presented in Fig. 6a. An
intact GCL was evident in PBS control animals (upper
left panel) or animals receiving reverse peptide, Aβ42–1
(not shown). Animals receiving intrahippocampal injec-
tion of Aβ1–42 exhibited a marked decrease of GCL neu-
rons (lower left panel). The administration of SB332235
with peptide to animals markedly attenuated neuronal
loss (lower right panel). Animals receiving SB332235
treatment in the absence of Aβ1–42 (upper right panel)
showed similar patterns of NeuN staining as for PBS
control.
Overall (N = 5 animals/group), Aβ1–42 injection caused
a considerable loss of GCL neurons with levels of NeuN
ir diminished by 56 % compared with PBS injection
(Fig. 6b). However, SB332235 treatment conferred a sig-
nificant degree of neuroprotection with numbers of neu-
rons increased by 36 % compared to NeuN ir with
peptide alone. Similar magnitudes of GCL neuron viabil-
ity were determined for both controls (PBS and Aβ42–1)
and SB332235 applied alone.neurons. a Representative neuronal staining (NeuN) in PBS control
l), and Aβ1–42 + SB332235 (lower right panel); results are for 3 days
nimal groups, N = 5 per group. Asterisk denotes p < 0.05. c Typical lipid
tion of PBS (upper left panel), SB332235 alone (upper right panel), Aβ1–
or 50 μm. d Area density of 4-HNE for the different animal treatments,
–42 + SB332235
Fig. 7 Effects of SB332235 on superoxide activity and inflammatory
factors. a Representative superoxide ir (HEt) in region adjacent to GCL
after 3 days intrahippocampal injection of PBS (upper left panel),
SB332235 alone (upper right panel), Aβ1–42 (lower left panel), and
Aβ1–42 + SB332235 (lower right panel); scale bar is for 120 μm.
b Quantification of intensity of HEt for the different animal groups;
N = 5 per group; *p < 0.05 for Aβ1–42 vs PBS and #p < 0.05 for Aβ1–42
vs Aβ1–42 + SB332235
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The relevance of oxidative stress and lipid peroxidation
as a contributing factor to neuronal damage and cogni-
tive deficiency has been indicated [32, 33]. We investi-
gated if oxidative stress might be involved in neuronal
damage in peptide-injected brain and if SB332235 could
protect against oxidative-mediated activity. Experiments
were designed to examine the overall changes in the
lipid peroxidation product 4-hydroxynonenal (4-HNE)
which is produced in cells under oxidative stress. These
measurements were taken in the GCL region of dentate
gyrus to relate oxidative effects to GCL neurons.
Typical staining patterns for 4-HNE are shown in
Fig. 6c. Minimal 4-HNE ir was observed with PBS
(upper left panel) or reverse peptide (data not shown)
injections indicating a lack of oxidative damage in con-
trols. However, considerable extents of 4-HNE staining
were present in the Aβ1–42-injected rat hippocampus
(lower left panel). Administration of SB332235 to
peptide-injected animals was effective in reducing levels
of lipid peroxidation product (lower right panel). The
treatment of animals with SB332235 alone was without
effect in induction of 4-HNE (upper right panel).
Quantification of data (N = 5 animals/group) indicated
little or no measurable 4-HNE ir in PBS or reverse pep-
tide controls whereas intrahippocampal peptide injection
induced considerable lipid peroxidation product (Fig. 6d).
Antagonism of CXCR2 with SB332235 reduced levels of
4-HNE (by 64 %) when applied to peptide-injected ani-
mals. Application of SB332235 alone had no effect on 4-
HNE area density.Effects of SB332235 on superoxide
A plethora of pro-inflammatory factors have been docu-
mented in AD brain [1]. Oxidative stress [34] and subse-
quent neuronal degeneration in peptide-injected inflamed
brain could be mediated by superoxide production from
activated microglia [35–37]. We used HEt as a cell-
permeable probe to detect levels of superoxide adjacent to
the GCL region. No evidence for HEt ir was found in
PBS-injected animal brain (upper left panel, Fig. 7a) or in
animals receiving reverse peptide injection (data not
shown). Intrahippocampal Aβ1–42 injection caused a
marked HEt ir (lower left panel) which was considerably
attenuated with SB332235 treatment of peptide-injected
animals (lower right panel). SB332235 administration
alone produced minimal levels of superoxide (upper right
panel).
The extent of HEt ir is shown in bar graphs (Fig. 7b)
for the different animal treatments (N = 5 animal/group).
Negligible HEt staining was evident for PBS and reverse
peptide controls or for rats administered SB332235
alone. A high HEt ir was measured in Aβ1–42-injectedrat brain with SB332235 treatment of peptide-injected
animals significantly reducing levels of HEt ir by 55 %.
Discussion
This study presents novel findings for enhanced expres-
sion of the chemokine IL-8 receptor CXCR2 in human
AD brain and in ML region of dentate gyrus in Aβ1–42-
injected rat hippocampus. Evidence is presented in the
AD animal model indicating upregulation of CXCR2
may be linked with microglial-mediated responses which
in turn are correlated with neuronal damage in inflamed
brain. In essence, deposition of Aβ1–42 induces a micro-
glial chemotactic response involving upregulation of
CXCR2 and its ligand, IL-8. A net migration of microglia
is manifest in clustering of cells in the vicinity of peptide
leading to cell activation and subsequent production of
an assemblage of pro-inflammatory mediators. Our find-
ings suggest microglial-derived oxidative species and
lipid peroxidation could contribute to oxidative stress
damage to GCL neurons with pharmacological inhib-
ition of CXCR2 efficacious in blocking inflammatory re-
activity and attenuating neuronal damage.
The demonstration of upregulated CXCR2 in AD vs
ND cortical brain tissue served as a rationale for the de-
sign of animal model experiments. Importantly, cortical
brain tissue from AD individuals demonstrated areas of
CXCR2 co-localization with activated microglia. Similar
results were obtained in hippocampal brain sections in
the few cases where tissue was available. The cell-
specific association of CXCR2 supports the possibility
that microglial-mediated inflammatory responses may be
involved in AD pathology. Involvement of CXCR2 acti-
vation in inflamed brain is consistent with the finding
that the receptor ligand, IL-8, is reported as the most
highly upregulated factor from Aβ1–42-stimulated human
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microglia subsequently exposed to Aβ1–42 has been
found to enhance cellular production of a host of in-
flammatory factors including pro-inflammatory cyto-
kines [13].
The intrahippocampal injection of Aβ1–42 is an AD
animal model characterized by enhanced inflammatory
reactivity with pharmacological block of microgliosis
correlated with increased viability of GCL neurons [25,
26, 30, 38]. In the present work, expression of CXCR2
and IL-8 showed similar time-dependent (1–7 days) in-
creases following Aβ1–42, relative to controls (PBS and
reverse peptide), intrahippocampal injection. Both re-
ceptor and ligand expressions were maximal at 3 days
post-peptide injection and remained elevated at 7 days
post-injection. Immunohistochemical staining exhibited
similar results with Aβ1–42 injection yielding a fivefold
increase in CXCR2 expression with Aβ1–42, relative to
PBS, injection (time point of 3 days post-injection). Re-
sults from Western blot assay showed consistent trends
in CXCR2 expression with duration of peptide injection
with CXCR2 levels maximum at 3 days post-peptide
injection.
At 3 days post-peptide injection, considerable extents
of CXCR2 immunoreactivity were co-localized with
microglia with lesser association of receptor with astro-
cytes (Fig. 3). Pharmacological antagonism of CXCR2 by
SB332235 was examined with an initial focus on drug ef-
fects on gliosis at 3 days subsequent to intrahippocampal
injection of Aβ1–42. A marked enhancement for both
microgliosis and astrogliosis was evident in ML region
of dentate gyrus compared with PBS or reverse peptide
application (Fig. 4). Treatment of peptide-injected ani-
mals with SB332235 significantly inhibited microgliosis
but was ineffective in attenuating astrogliosis. It can be
noted that contributions from CXCR2-(+)ve neurons
would be minimized in sections isolated from the ML
region. In addition, the absence of myeloperoxidase
(MPO) immunoreactivity (data not shown) indicated
that CXCR2-mediated neutrophils did not contribute to
inflammatory responses in Aβ1–42-injected rat brain.
Microglial chemotaxis is a rapid inflammatory re-
sponse to Aβ deposition in the AD model [7, 26]. In this
work, we measured net migration of microglia in a sin-
gle quadrant in the immediate vicinity of peptide de-
posits in ML. Double staining was then used to
determine CXCR2 and glial ir within 300 μm of Aβ1–42
deposits (Fig. 5). Animal treatment with SB332235 was
examined for localized effects on CXCR2 area density
and microgliosis and astrogliosis. Both CXCR2 area
density and microglial ir were significantly attenuated by
SB332235 administration with no effects of the com-
pound on astrocytic responses. Although this compo-
nent of study does not directly target chemotacticprocesses, the results suggest efficacy for SB332235 in
inhibiting microglial responses and CXCR2-dependent
activity nearby peptide.
Peptide-injected (3 days) rat brain exhibited a consid-
erable loss of GCL neurons compared to PBS or reverse
peptide injection (Fig. 6a, b). Treatment of Aβ1–42-
injected rats with SB332235 conferred a significant de-
gree of neuroprotection as shown by NeuN staining in
the GCL region of dentate gyrus. Previous work using
this animal model has demonstrated that drug actions
which inhibit microgliosis are correlated with enhance-
ment in numbers of GCL neurons [6, 26]. We also ex-
amined if lipid peroxidation could contribute to
neurotoxicity by assessing 4-HNE ir in the GCL region.
Overall, levels of 4-HNE were markedly elevated with
Aβ1–42, and absent with PBS or Aβ42–1, intrahippocam-
pal injection (all results obtained at 3 days post-
injection). Animal treatment with SB332235 markedly
inhibited 4-HNE levels in peptide-injected brain.
Previous work has demonstrated peptide-stimulated
microglia as a prominent source of superoxide radical [35,
36]. Oxidative stress induced by superoxide species could
be involved in the lipid peroxidation damage to neurons
[34]. To examine this possibility, HEt ir was determined in
the ML region of dentate gyrus. This region was chosen to
correspond to the areas of microglial and astrocytic re-
sponses. Superoxide was not detectable in controls (PBS
or Aβ42–1) at 3 days post-injection; however, considerable
HEt ir was evident in Aβ1–42-injected brain. Treatment of
peptide-injected animals with SB332235 was effective in
attenuating levels of the superoxide marker. The neuro-
protection conferred by SB332235 is consistent with pre-
vious results showing inhibition of microgliosis as a
mechanism enhancing neuronal viability in the peptide-
injected animal model but does not rule out possible dir-
ect effects of the CXCR2 antagonist on GCL neurons.
As noted above, direct intrahippocampal injection of
Aβ1–42 serves as an AD animal model which exacerbates
inflammatory reactivity. The model appears to be char-
acterized as one in which an acute insult evolves into a
chronic inflammatory perturbation in a relatively short
time. The injection of peptide has particular utility in
correlating effects of pharmacological modulation of
microgliosis with viability of neurons. Validation of the
model has been considered in terms of a comparison of
cellular responses and processes with properties charac-
teristic of AD brain tissue [39]. This comparison has
shown similarities in a number of features including
microglial and astroglial responses, abnormalities in mi-
crovasculature, and leakiness in BBB. Neuronal loss ap-
parent in the AD model is the correlate of cognitive
dysfunction in AD brain.
Our in vivo results provide evidence for efficacy of
SB332235 at a time point associated with maximal
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PCR data suggest that both receptor and ligand expres-
sions may remain elevated over longer times. In AD
brain, expression of CXCR2 (Fig. 1) and IL-8 [12] is in-
creased compared to levels in controls. In this case, the
CXCR2 antagonist may have utility in reducing chronic
inflammatory activity over extended times.
It is important to note that beneficial effects of micro-
glial response and activation have been reported in AD
brain [40–42]. Indeed, previous work on chemokine re-
ceptors in Tg 2576 mice has demonstrated that attenu-
ation of Ccr2 in microglia was associated with abnormal
accumulation of Aβ and increased mortality of animals
[43]. Conversely, knockout of chemokine receptor Cx3cr1
was found to confer neuroprotection in a mouse model of
AD [44]. Overall, a manifold of microglial-mediated in-
flammatory pathways is active in peptide-stimulated brain
[1, 45] with diverging negative or positive effects on the
viability of the neurovascular unit [46].
Our findings suggest the relevance in using transgenic
animal models to examine pharmacological inhibition of
CXCR2 as a strategy to enhance cognitive function. Such
studies would reflect the effects of a progressive buildup
of peptide deposits over time, rather than direct injec-
tion of amyloid, to more closely mimic chronic inflam-
mation in AD brain. It should be emphasized that a
number of chemokines, their receptors, and a host of
non-chemokine factors could contribute to inflamma-
tory reactivity in the progression of AD pathology. We
suggest the merits in using a cocktail delivery of drugs
as a strategy to examine effects for modulation of mul-
tiple components of chronic inflammation in treatment
of the disease.Conclusion
Overall, this study has demonstrated competitive antag-
onism of CXCR2 as an effective strategy in attenuating
chemokine receptor expression in microglia, the accu-
mulation of microglia nearby peptide, and the cellular
production of superoxide. The inhibition of a spectrum
of inflammatory processes is correlated with an en-
hanced viability of granule cell neurons. Since CXCR2
and its ligand IL-8 are upregulated in AD, relative to
ND, brain, modulation of CXCR2 represents a novel
neuroprotective strategy to be tested in other AD animal
models.
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